目的 基于症状评分和健康状态比较氟替美维吸入粉雾剂及布地格福吸入气雾剂治疗重度慢性阻塞性肺疾病(COPD)的临床疗效。方法 回顾性选择重度COPD的患者66例,分为氟替卡松/乌美溴铵/维兰特罗(FF/UMEC/VI)组和布地奈德/格隆溴铵/福莫特罗(BUD/GLY/FOR)组。比较两组患者在单一吸入器三联治疗(SITT)药物1个月时的症状评分和健康状态并回顾性分析 FF /UMEC/VI 组短期及长期使用的症状变化。结果 纳入35例FF /UMEC /VI 组和31例BUD /GLY /FOR 组患者。与治疗前比较,两种SITT药物COPD评估测试(CAT)评分、改良版英国医学研究委员会(mMRC)呼吸困难评分和6 min步行试验(6 MWT)数值在治疗1个月时均有改善,差异有统计学意义(P＜0.05)。与BUD/GLY/ FOR组相比,FF/UMEC/ VI组治疗1个月时mMRC评分(U=-2.277, P＜0.05)和6 MWT数值(U=-3.993, P＜0.05)较基线改善更多,差异有统计学意义。FF/UMEC/VI组维持治疗8个月比3个月时症状评分和健康状态改善更大,但差异无统计学意义。结论 治疗1个月时氟替美维吸入粉雾剂在改善重度COPD患者症状评分和健康状态方面优于布地格福吸入气雾剂。
Abstract
Objective To compare the clinical efficacy of fluticasone/umeclidinium/vilanterol(FF/UMEC/VI) inhalation powder and budesonide/glycopyrrolate/formoterol (BUD/GLY/FOR) inhalation aerosol in the treatment of severe chronic obstructive pulmonary disease (COPD) based on symptom scores and health status. Methods A total of 66 patients with severe COPD were retrospectively selected and divided into a FF/UMEC/VI group and a BUD/GLY/FOR group. The health status and symptom scores of the two groups were compared at 1 month of single inhaler triple therapy (SITT) drug use, and the short-term and long-term symptom changes of the FF/UMEC/VI group were retrospectively analyzed. Results The FF/UMEC/VI group had 35 patients, and the BUD/GLY/FOR group had 31 patients. Compared with before treatment, there was significant improvement in COPD assessment test (CAT) score, mMRC score, and 6MWT at 1 month of treatment in both groups, and the differences were statistically significant (P<0.05). Compared with the BUD/GLY/FOR group, the mMRC score (U=-2.277, P<0.05)and 6MWT (U=-3.993,P<0.05) of the FF/UMEC/VI group improved at 1 month of treatment, with statistically significant differences. In the FF/UMEC/VI group, the symptom score and health status improved more at 8 months of maintenance treatment than at 3 months, but the difference was not statistically significant. Conclusions At 1 month of treatment, FF/UMEC/VI inhalation powder is superior to BUD/GLY/FOR inhalation aerosol in improving the symptom scores and health status of the patients with severe COPD.
关键词
氟替美维 /
布地格福 /
CAT评分 /
改良版英国医学研究委员会呼吸困难评分 /
6 min步行试验
Key words
FF/UMEC/VI /
BUD/GLY/FOR /
CAT score /
mMRC score /
6MWT
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] deOca M M,Perez P R,Celli B,et al.The global burden of COPD: epidemiology and effect of prevention strategies[J].Lancet Respir Med,2025,13(8):709-724.
[2] Sansbury L B,Bains C,Lipson D A,et al.Real world treatment patterns of multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in UK general practice[J].Int J Chron Obstruct Pulmon Dis, 2021,16:1255-1264.
[3] Zeng Y,Cai S,Chen Y,et al.Current status of the treatment of COPD in China: a multicenter prospective observational study[J].Int J Chron Obstruct Pulmon Dis,2020,15:3227-3237.
[4] Voorham J,Corradi M,Papi A,et al.Comparative effectiveness of triple therapy versus dual bronchodilation in COPD[J].ERJ Open Res,2019,5(3):106-129.
[5] Zayed Y,Barbarawi M,Kheiri B,et al.Triple versus dual inhaler therapy in moderate-to-severe COPD: a systematic review and meta-analysis of randomized controlled trials[J].Clin Respir J,2019,13(7): 413-428.
[6] Criner G J,Lipson D A,Tombs L,et al.Effects of seasonality and treatment on COPD clinical outcomes: IMPACT post hoc analysis[J].ERJ Open Res,2025,11(1):135-157.
[7] Nannini L J.Mitigating systemic corticosteroid risks in COPD: a call for earlier triple therapy initiation[J]. Pulm Pharmacol Ther,2025,90:102360.
[8] Jones P W,Harding G,Berry P,et al.Development and first validation of the COPD assessment test[J].Eur Respir J,2009,34(3):648-654.
[9] Bestall J C,Paul E A,Garrod R,et al.Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease[J].Thorax,1999,54(7):581-586.
[10] Hernandes N A,Wouters E F,Meijer K,et al.Reproducibility of 6-minute walking test in patients with COPD[J]. Eur Respir J,2011,38(2):261-267.
[11] Wang J G,Bose S,Holbrook J T,et al. Clinical characteristics of patients with COPD and comorbid depression and anxiety: data from a national multicenter cohort study[J].Chronic Obstr Pulm Dis,2025,12(1): 33-42.
[12] Penedones A,Mendes D,Alves C,et al.Relationship between chronic obstructive pulmonary disease and osteoporosis: a scoping review[J]. COPD,2024,21(1):2356510.
[13] Agustí A,Celli B R,Criner G J,et al.Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary[J].Arch Bronconeumol,2023,59(4):232-248.
[14] Katsiki N,Steiropoulos P,Papanas N,et al.Diabetes mellitus and chronic obstructive pulmonary disease: an overview[J].Exp Clin Endocrinol Diabetes,2021,129(10):699-704.
[15] Leitner M,Blum A M,Bals R.Update COPD and cardiovascular events[J].Dtsch Med Wochenschr,2025, 150(6):298-302.
[16] Eilat-Tsanani S,Ernst P,Suissa S.Real-world effectiveness of single-inhaler triple therapy for COPD: impact of diabetes comorbidity[J].COPD,2024,21(1):2327345.
[17] Su H,Li F,Li J.The analysis of risk factors associated with readmission in patients with exacerbation of COPD[J].Medicine,2025,104(23):e41997.
[18] Lee S D,Huang M S,Kang J,et al.The COPD assessment test (CAT) assists prediction of COPD exacerbations in high-risk patients[J].Respir Med,2014,108(4):600-608.
[19] Lipson D A,Barnhart F,Brealey N,et al.Once-daily single-inhaler triple versus dual therapy in patients with COPD[J].N Engl J Med,2018,378(18):1671-1680.
[20] Lipson D A,Barnacle H,Birk R,et al.Fulfil trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease[J].Am J Respir Crit Care Med,2017,196(4):438-446.
[21] Muro S,Seki M,Hurst J R,et al.Triple therapy with budesonide/glycopyrronium/formoterol fumarate dihydrate versus dual therapies for patients with COPD and phenotypic features of asthma: a pooled post hoc analysis of kronos and ethos[J].Int J Chron Obstruct Pulmon Dis,2024,19:2729-2737.
[22] Ferguson G T,Rabe K F,Martinez F J,et al.Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial[J].Lancet Respir Med,2018,6(10):747-758.
[23] Rabe K F,Martinez F J,Ferguson G T,et al.Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD[J].N Engl J Med,2020,383(1):35-48.
[24] 何 婷,赵青青,徐存来.三联复方吸入气雾剂治疗慢性阻塞性肺疾病的效果及对肺功能、血气及炎症的影响[J].空军军医大学学报,2025,46(9):1218-1223.
[25] Ismaila A S,Haeussler K,Czira A,et al.Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy compared with other therapies for the treatment of COPD: a network meta-analysis[J].Adv Ther,2022, 39(9):3957-3978.
[26] Wedzicha J A,Noorduyn S G,Boscio V,et al.Comparative effectiveness of FF/UMEC/VI and BUD/GLY/FORM in patients with COPD stepping up from dual therapy[J].Adv Ther,2025,42(9):4432-4446.
PDF(977 KB)
